1 / 30

Cerus Corporation June 2011

Cerus Corporation June 2011. The INTERCEPT Blood System: Securing Safety & Availability. Forward Looking Statements.

dara
Download Presentation

Cerus Corporation June 2011

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cerus CorporationJune 2011 The INTERCEPT Blood System: Securing Safety & Availability

  2. Forward Looking Statements The following presentation includes forward-looking statements relating to Cerus’ business and clinical prospects and opportunities, including Cerus’ commercialization efforts, potential market opportunities for the INTERCEPT Blood Systems, potential regulatory approvals and timelines related to the INTERCEPT Blood Systems, potential efficacy of the INTERCEPT Blood Systems and Cerus’ plans to pursue further development thereof, future milestones, including clinical trial initiation and completion, financial projections, including Cerus’ expectations of 2011 revenue and annual growth rate, and statements related to potential near-term profitability, and Cerus’ expectations, beliefs and plans, which involve significant risks and uncertainties. There are important factors that could cause actual events and performance to differ materially from Cerus’ forward-looking statements, including without limitation risks and uncertainties related to commercial adoption and market acceptance of the INTERCEPT Blood Systems, Cerus’ ability to effectively commercialize the INTERCEPT Blood Systems, reimbursement availability, competition, manufacturing and product supply, Cerus’ reliance on third parties for sales, marketing and regulatory support, Cerus’ ability to obtain and maintain domestic and foreign regulatory approvals, clinical trials and other development activities, protection of intellectual property rights, rate of consumption and sufficiency of Cerus’ current cash reserves, accounting practices, currency exchange rates, Cerus’ need for additional capital, and other risks and uncertainties disclosed from time to time in reports filed by Cerus with the Securities and Exchange Commission, including Cerus’ quarterly report on Form 10-Q for the quarter ended March 31, 2011. All forward-looking statements speak only as of the time when made; Cerus undertakes no obligation to update any such forward-looking statements to reflect any future events or developments.

  3. Corporate Overview • Founded in 1991; IPO in 1997 (NASDAQ: CERS) • Headquarters in California and the Netherlands • ~75 employees worldwide • Focused on INTERCEPT pathogen inactivation (PI) for blood components to improve transfusion safety • Drug/device combination approved in Europe for platelets & plasma • In Phase III clinical development for red blood cells • Growing number of national mandates are establishing PI as EU standard of care

  4. Blood Transfusion is a Fundamental Need • Market for safer blood transfusions is large and growing • Nearly 100 million transfusions annually, 3 per second* • Global opportunity >$6 billion • Blood components remain vulnerable to infectious threats • After 25 years of testing, partial protection against just 7 agents • HIV, Hepatitis B, Hepatitis C, HTLV, syphilis, West Nile virus, bacteria • Bacterial contamination remains a significant threat • Additional pathogens continue to emerge • SARS, Dengue, Chagas’ disease, Babesia Parasites White Cells Viruses Bacteria Spirochetes *Sources: Marketing Research Bureau Inc. and industry data

  5. Bacterial Contamination of Platelets:Severe and Even Fatal Reactions Continue to Be Reported Death of a pediatric patient after transfusion of a PLT unit contaminated with Klebsiellapneumoniaein Geneva(February 2009)

  6. Sepsis is Not Reported in INTERCEPT Platelet Recipients:French Experience – Hemovigilance Data 2006-09 Agence Francaise de Securite Sanitaire des Produits de Sante (2006-2009). Rapport Hemovigilance 2006. Paris, Afssaps. Kientz et al. 13th International Haemovigilance Seminar (IHS) Amsterdam, The Netherlands February 9 - 11th, 2011

  7. Platelet, Plasma & Red Cell Characteristics PLATELETS PLASMA RED CELLS Control of bleeding Platelets are necessary to prevent bleeding and support blood coagulation. Who needs platelets? • Cancer • Stem cell transplant • Major surgical procedures • Trauma Delivering coagulation factors Plasma is necessary to provide coagulation factors to prevent and treat bleeding. Who needs plasma? • Major surgical procedures • TTP • Trauma • Liver disease • Congenital factor deficiencies Delivery of oxygen Red blood cells contain hemoglobin, which allows them to deliver oxygen to tissues and return carbon dioxide to the lungs. Who needs red cells? • Trauma • Surgery • Anemia • Sickle cell disease & thalassemia 42 1 4-7 DAYS YEAR DAYS SHELF LIFE room temperature refrigerated frozen FREQUENTLY TRANSFUSED PATIENTS Thrombotic thrombo-cytopenicpurpura (TTP) requires total plasma exchange, a treatment with up to 200 units of plasma. A cancer patient undergoing bone marrow transplant may need up to 120 units of platelets during transfusion support. Sickle cell disease and thalassemia patients may be transfused with ~30 units per year, or over 1000 units over a lifetime.

  8. INTERCEPT Blood System Product Pipeline Phase I / II Phase III Marketing EU & ROW Platelets Plasma Red Cells USA Platelets1 Plasma2 Red Cells One U.S. Phase III trial completed; additional Phase III data required. Orphan drug designation for treatment of TTP; approval requirements in discussion with FDA.

  9. >$6 B Global Market Potential for INTERCEPT $ MM * Current markets

  10. Blood Collection, Processing & Distribution Blood Center Hospital Donor Recruitment & Screening Blood Collection Infectious Disease Testing Transport to Hospital Component Processing [INTERCEPT treatment] Storage Transfusion Plasma Fractionator Plasma Only Albumin Storage Fractionation Process IVIG Follow-up (reactions or infections) etc

  11. Industry Landscape for Blood Collection & Transfusion 11

  12. INTERCEPT Blood System Profile

  13. Mechanism of Action • Small molecule amotosalenHCl penetrates cellular and nuclear membranes intercalating into helical regions of DNA or RNA present in pathogens • Covalent crosslinks to nucleic acid base pairs form upon exposure to UVA light • DNA and RNA replication are blocked, inactivating pathogens and leukocytes • INTERCEPT for red blood cells uses a different molecule (S-303) that forms crosslinks after activation by physiological pH UVA illumination or pH reaction Amotosalen Nucleic acid intercalation Docking Crosslinking Unable to replicate

  14. HIV-1HIV-2HBVHCVHTVL-IHTLV-II Proactive Approach to Blood Safety Routinely tested agents CERUS’S COMPREHENSIVE SPECTRUM PROTECTION GRAM-NEGATIVE BACTERIA SPIROCHETESTreponema pallidumBorrelia burgdorferi PROTOZOA Trypanosoma cruziPlasmodium falciparumLeishmania sp. Babesia microti LEUKOCYTEST-cells ENVELOPED VIRUSES DHBVBVDVCMVWNVSARSVaccinia1ChikungunyaDengue2Influenza A ENVELOPED VIRUSES Klebsiella pneumoniaeYersinia enterocoliticaEscherichia coliPseudomonas aeruginosaSalmonella choleraesuisEnterobacter cloacaeSerratia marcescensAnaplasma phogocytophilumOrientia tsutsugamushi3 HIV-1HIV-2HBVHCVHTLV-IHTLV-II NON-ENVELOPED VIRUSES GRAM-POSITIVE BACTERIA Staphylococcus epidermidis Staphylococcus aureusStreptococcus pyogenes Listeria monocytogenes Corynebacterium minutissimum Bacillus cereus (vegetative) Lactobacillus sp. Bifidobacterium adolescentisPropionibacterium acnesClostridium perfringens SPIROCHETES Bluetongue virus, type 11Simian Adenovirus-15Feline calicivirus Parvovirus B19Human adenovirus 5 Treponema pallidum (1) Sampson-Johannes A, et al. 2003. Transfusion. 43:83A; (2) Lam S, et al. Transfusion 2007;47:131A; (3) Rentas F. Transfusion 2004;44:104A.

  15. Efficient, Robust, Flexible Technology Platelets Step 1 Amotosalen Step 2 Illumination Step 3 CAD Process Complete Storage Plasma

  16. INTERCEPT Benefits Go Beyond Safety:Logistical Advantages Lower Costs & Improve Platelet Availability Before Culture/PI Bacterial Culture INTERCEPT PI Inactivation Collection Day 7 Day 6 Day 5 Day 1 Day 3 Day 2 Day 4 Serology/NAT Preincubation Day 0 Begin culture Release Release Release“negative to date” Outdate Outdate 10-20% ~20% ~5% Approx Discards

  17. U.S. Market & Red Blood Cells (RBC) Development Programs

  18. FDA Approval Pathway in U.S. • Orphan drug designation for plasma • Designation awarded February 2011: treatment of TTP patients • Phase 3 pivotal TTP trial previously completed • Next step: initiate FDA discussion of requirements for orphan PMA approval • Phase III trial designs to be negotiated for red cells and platelets • Phase I successfully completed for red cells in 2010, met FDA criteria; Phase III trial design to be discussed • Additional Phase III trial required for platelets; FDA wants more safety data, trial design under discussion • FDA dialogue ongoing 18

  19. RBC Program in Europe: Entering Phase III • Pivotal Phase III program planned with European regulators • Finalizing CTA • Expecting acute cardiovascular and chronic thalassemia trials • Planned initiation of acute trial by end of 2011 • Prioritizing fastest route to market • Acute clinical trial is shorter; file CE mark for acute indication first • Finish chronic trial and application in parallel with market launch • Cerus RBC collaborations and grant funding • French National Blood Service (EFS) • German Red Cross (Frankfurt) • Grifols • U.S. Department of Defense

  20. INTERCEPT in Europe, CIS & Middle East Current Markets

  21. Current INTERCEPT Markets • Routine use at over 80 centers in 15 countries • Concentrated market with many national blood services • Centralized decision-making : Routine Customers

  22. Competitive Landscape for Blood Component Pathogen Inactivation INTERCEPT provides the most robust solution: • Satisfies highest regulatory standards for PI systems • Broadest spectrum of inactivation against current & emerging pathogens • Extensive clinical and hemovigilance data (>60,000 transfusions monitored)

  23. Switzerland: Pediatric Fatality in Geneva Caused Reevaluation of Platelet Safety 13 Regional Swiss Red Cross Blood Centers Red Cross signs INTERCEPT contract Pediatric fatality Mandate for platelet PI Target conversion to 100% platelet PI 2009 2010 2011 2012 INTERCEPT plasma approval INTERCEPT platelet approval

  24. Swiss Red Cross Implementation Status – May 2011

  25. Leveraging PI “tipping points” for standard of care in transfusion medicine • Adoption within a country • Blood centers look at neighboring centers to establish best practices • Local governments / Ministries of Health may mandate higher safety standards • Influence between countries • Many centers are influenced by the adoption practices of other countries, especially national mandates • Broader adoption can also influence pan-European health policies • Synergies within a center from multiple PI treatments • Blood centers want PI for all three blood components to maximize safety • Advantages for treatment of multiple components on one platform • PI for all three components also maximizes potential cost savings

  26. Financials & Summary

  27. Year over Year INTERCEPT Revenue Momentum 2006-2010 (4 year) CAGR for revenue >60% 27

  28. Financial Highlights (as of Mar 31, 2011) • Cash: $24.4 million • Shares Outstanding: 47,450,000 • 2011 earnings guidance • Continued robust market penetration; 20%+ total revenue growth • Q1 sales: $6.2 M • Credit facility : $10M facility, $5M available • ~12% interest – 9 mos interest only + 30 months amortizing

  29. Investment Summary:Well Positioned for Further Growth • Leverage European infrastructure to increase market penetration • Establish pathogen inactivation as new standard of care • Define clear pathway to U.S. approval for all three programs • Discussing broad platelet indication approval path with FDA • Granted orphan status for plasma for TTP • Orphan drug approach changes risk/benefit equation with FDA • Pursue new partner for INTERCEPT in Asia • Regained Asian rights from BioOne in Q3 2010 • Advance red blood cell program • Preparing for Phase III study seeking initial EU approval

  30. Global Headquarters 2550 Stanwell Drive Concord, California USA 94520 Phone: (925) 288-6000 European Headquarters Stationsstraat 79-D 3811 MH Amersfoort, Netherlands Phone: +31 (0) 33 49 60 600

More Related